NORTH CHICAGO, Illinois, February 20, 2024 -- AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that its Board of Directors has unanimously selected Robert A. Michael, currently President and Chief Operating Officer, to become the company's next Chief Executive Officer, effective July 1, 2024. Richard A. Gonzalez, who has led AbbVie since its inception as an independent company in 2013, will transition to the role of Executive Chairman.

"Robert is an outstanding leader with deep expertise across our business and a proven track record of driving growth and innovation," said Richard A. Gonzalez. "Over his 31-year career, he has demonstrated exceptional strategic vision and operational excellence. I am confident he is the right leader to guide AbbVie into its next phase of growth."

Michael brings 31 years of experience spanning pharmaceuticals, aesthetics, diagnostics, diabetes care, and nutrition. He began his career with Abbott in 1993 through the company's financial development program and has held increasingly senior roles throughout his tenure. He was appointed Chief Financial Officer in 2018, Vice Chairman of Finance and Commercial Operations in 2021, and Vice Chairman and President in 2022 before assuming his current position as President and Chief Operating Officer in 2023.

"I am honored by the Board's confidence and excited about the opportunity to lead AbbVie," said Robert A. Michael. "Richard has built an incredible foundation, transforming AbbVie into one of the world's leading biopharmaceutical companies. I look forward to working with our talented team to continue delivering life-changing medicines to patients around the world."

Under Gonzalez's leadership, AbbVie has grown from a market capitalization of approximately $54 billion at the time of separation from Abbott in 2013 to more than $300 billion today. During this period, the company's revenue has nearly tripled, and adjusted diluted earnings per share has grown from $2.93 to $11.11.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company founded in 2013. The company discovers and delivers innovative medicines and solutions across immunology, oncology, neuroscience, eye care, and aesthetics. AbbVie's medicines and products reach patients in more than 175 countries, serving over 60 million people worldwide.
